Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood treatment boost IVF success? new trial investigates

NCT ID NCT07306871

Disease control Sponsor: Minia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether platelet-rich plasma (PRP), made from a woman's own blood, can improve pregnancy rates in those who have had multiple failed embryo transfers. 180 women will receive PRP either as an injection into the uterus lining or as a simple infusion, and their outcomes will be compared to a group receiving standard care. The goal is to see which method works better for helping embryos implant successfully.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
platelet-rich plasma (PRP)
What this could lead to
If it works, this could offer a simple, low-cost way to improve pregnancy rates for women who have repeatedly failed embryo transfers.
What could go wrong
This is a small, early-stage trial with 180 participants, and PRP is not a standard treatment. Results may not show a clear benefit, and the procedure carries minor risks like infection or discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 -40 years . * BMI\<30 Kg/m2. * An IVF procedure resulting in at least one top quality embryo . * At least one cancelation history of embryo transfer due to thin endometrium (failure of achieving 7 mm endometrial thickness in the cycle) in frozen embryo transfer (FET) cycles after receiving standard hormone therapy. * Women had a history of failure to achieve pregnancy after two or more embryo transfers with high-quality embryos. Exclusion Criteria: * women with other factors that may affect implantation success are excluded: ; * BMI \>30 kg/m2. * Untreated uterine abnormalities. * untreated hydrosalpinges. * Thrombophilia. * uncontrolled endocrinopathy * severe male factor infertility. * difficult embryo transfer. * only poor quality embryos available . * couple with chromosomal abnormalities * Hematological disorders (blood cancer ,thrombocytopenia ) * Hormonal disorders (DM,thyroid disorders ) * Immunological disorders (anti phospholipid syndrome). * renal failure * Genetic ,chromosomal abnormalities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Compare between subendometrial injection and intrauterine infusion of PRP in recurrent implantation failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Compare between subendometrial injection and intrauterine infusion of PRP in recurrent implantation failure Infertility Recurrent implantation faliure

Contacts and locations

Locations

  • Minia University

    Minya, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.